Omacetaxine mepesuccinate regulatory update

Teva said FDA accepted for review an NDA for omacetaxine to treat chronic myelogenous leukemia (CML) in patients who have resistance and/or intolerance to two or more tyrosine kinase inhibitors, inclu...